These awards honour individuals and organizations who have made significant contributions to strengthening the BC clinical trials ecosystem. Submit your nominations by December 10, 2023.
The recipients are honoured for their significant contributions and impacts to the clinical trials community in BC and beyond.
The objective of this request is to fund trials evaluating products from Canadian-controlled biotechnology companies in partnership with ACT Network clinical trialists.
We’re pleased to announce a renewed province-wide membership agreement with N2 (Network of Networks).
The US Federal Drug Administration released a new draft document titled ‘Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers” on March 12, 2023
Questions: What is the definition of a true or certified copy in Canada? Are we allowed to transfer the Clinical Trial Essential Records from the original medium to another media during the study and at the time of archive?
Question: Do investigators and institutions have to provide direct access to source data and documents related to a clinical trial monitoring, REB review, audits, and regulatory inspection?
Consultation has re-opened for the proposed agile regulations and guidance for licensing drugs and medical devices in Canada.
Join us in the 2nd episode of ASK US season three. Learn from an expert panel of representatives who will share a host of tips, quips and archive stories.
Check out the updates on BC’s provincially-harmonized Clinical Trial Management System (CTMS). Over the last year, our program has seen significant growth and progress.